GeneDx Holdings (WGS) Non Operating Interest Expenses (2020 - 2023)

GeneDx Holdings (WGS) has reported Non Operating Interest Expenses for 4 consecutive years, with $626000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Non Operating Interest Expenses fell 20.76% year-over-year to $626000.0 in Q2 2023; TTM through Jun 2023 was $3.0 million, a 0.47% change from a year earlier, with the FY2022 full-year figure at $3.2 million, up 13.12% from the prior year.
• Non Operating Interest Expenses was $626000.0 for Q2 2023 at GeneDx Holdings, down from $767000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $808000.0 in Q1 2022 and troughed at $626000.0 in Q2 2023.
• A 4-year average of $726666.7 and a median of $722500.0 in 2021 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses gained 18.01% in 2022 and declined 20.76% in 2023, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $648000.0 in 2020, then rose by 9.1% to $707000.0 in 2021, then increased by 13.58% to $803000.0 in 2022, then declined by 22.04% to $626000.0 in 2023.
• The last three Non Operating Interest Expenses figures came in at $626000.0 (Q2 2023), $767000.0 (Q1 2023), and $803000.0 (Q4 2022), per Business Quant data.